Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT04728893 : A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood

Systemic therapy | Blood / Myeloma / LymphomaChronic Lymphocytic Leukaemia,Follicular Lymphoma,Leukaemia,Lymphoma,Mantle Cell Lymphoma

Trial Overview Read MoreRead more

This phase II trial is trying to understand how safe and effective a targeted therapy (nemtabrutinib) is in people with blood cancers.

This trial is treating patients with chronic lymphocytic leukaemia/ small lymphocytic lymphoma, Richter's transformation, marginal zone lymphoma, mantle cell lymphoma, follicular lymphoma, and Waldenström's macroglobulinemia .

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

Commercial Sponsor



This is a non-randomised trial for people with haematological malignancies of chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM). The trial has two parts: Dose Escalation and Confirmation (Part 1) and Cohort Expansion (Part 2). Following determination of a recommended phase 2 dose (RP2D) in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A to H). Participants will receive nemtabrutinib orally once daily until progressive disease or discontinuation.

Recruiting Hospitals Read MoreRead more

Box Hill Hospital, Malignant Haematology
Box Hill
Ms Liz Arnold
03 9094 9516

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.